Non Interventional Study to Evaluate the Efficacy and Tolerability of Ectoin Containing Ophthalmic Solution
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This is a comparative, open label, parallel group, non interventional study to further demonstrate the efficacy and tolerability of BAT04. In addition the efficacy and safety shall be compared to Hyaluronic acid (HA)-Product. The patient applies BAT04 or HA-Product according to the instructions for use six times daily in both eyes over a period of 28 days. Response to treatment is recorded at day 28.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
primary care clinic The selection of appropriate patients for the observational study is made by the individual physician in his treatment decisions in consultation with the individual patient
Male or female person aged 18 years
Demonstrated mild to moderate keratoconjunctivitis sicca ( "dry eye")
Acute symptoms of dry eye: DEWS 1-3
tear break-up time TBUT <10s
agreement to abide by the routinely provided doctor's appointment for follow-up (reflected in the planned visits of observation plan resist)
inflammation of the anterior segment or trauma
Contact lens wearers
Any disease that can, in the opinion of the treating physician to affect the outcome of the study.
Patients with known intolerance to one of the substances used
Surgical procedures to the eyes in the last 6 weeks before inclusion in the trial
patients with addictive disorders or substance abuse fallow in the past 12 months, as well as persons incapable of giving consent